Since 2009, the multi-institutional collaboration to study the genomic characteristics of lung adenocarcinomas, The Lung Cancer Mutation Consortium (LCMC), has analysed data from 1900 NSCLC patients and showed that 27% of lung adenocarcinomas harboured a KRAS mutation and about 30% of them harboured another oncogenic driver, most frequently STK11 and LKB1 mutation [136]. Here, KRAS is linked to lung carcinoma.